Vistagen Therapeutics Inc
VTGNLatest QuantConomy context for VTGN: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Vistagen Therapeutics Inc
Vistagen Therapeutics Inc (VTGN) is a late clinical-stage biopharmaceutical company focused on pioneering neuroscience to develop and commercialize groundbreaking therapies for psychiatric and neurological disorders. The company is developing an innovative pipeline of Central Nervous System medications, including investigational pherine products such as Fasedienol for anxiety disorders, Itruvone for depression, PH80 for menopausal hot flashes, premenstrual dysphoric disorder, and migraine, and other potential treatments for sleep deprivation, cognitive impairment, and appetite-related disorders. Vistagen aims to establish new standards of care and radically improve mental health and well-being worldwide.
- Symbol
- VTGN
- Name
- Vistagen Therapeutics Inc
- Coverage
- 3 market/data records
- Sources
- alphavantage alpaca fmp sec nasdaq openfigi
Recent signals for VTGN
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| eps change | very bearish | 76 | Jun 15, 12:00 AM | VTGN (FY 2026, diluted eps): EPS declined 306.7% ($-0.45 → $-1.83). [sequential period basis, very bearish signal] |
| net income change | very bearish | 76 | Jun 15, 12:00 AM | VTGN (FY 2026, net income): declined 268.7% (-$18.90M → -$69.69M). [sequential period basis, very bearish signal] |
| operating income change | very bearish | 76 | Jun 15, 12:00 AM | VTGN (FY 2026, operating income): declined 269.0% (-$19.55M → -$72.13M). [sequential period basis, very bearish signal] |
FUNDAMENTAL signals are experimental: the generator was recently enabled and coverage is still being validated.
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| VTGN | NASDAQ | alphavantage | VistaGen Therapeutics Inc |
| VTGN | NASDAQ | alpaca | VistaGen Therapeutics, Inc. Common Stock |
| VTGN | NASDAQ | fmp | VistaGen Therapeutics, Inc. |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 18, 2026 | Angelov Angel S | Chief Medical Officer | grant | 150,000 | — | — | 4 on EDGAR |
| Apr 7, 2026 | Singh Shawn | President and CEO | grant | 3,732 | — | — | 4 on EDGAR |
| Apr 7, 2026 | Tressler Nick B. | Chief Financial Officer | grant | 75,000 | — | — | 4 on EDGAR |
| Apr 7, 2026 | Prince Joshua S. | Chief Operating Officer | grant | 18,752 | — | — | 4 on EDGAR |
| Apr 7, 2026 | Cote Elissa S. | Chief Corp Development Officer | grant | 75,000 | — | — | 4 on EDGAR |
| Apr 7, 2026 | Adler Reid G. | Chief Legal Officer | grant | 18,753 | — | — | 4 on EDGAR |
| Dec 31, 2025 | Prince Joshua S. | Chief Operating Officer | grant | 4,386 | $0.56 | $2,468 | 4 on EDGAR |
| Dec 1, 2025 | Tressler Nick B. | Chief Financial Officer | grant | 150,000 | — | — | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query VTGN context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access